Biotech Stocks' Research Reports Released on Repros Therapeutics, Aldeyra Therapeutics, Neothetics, and BioLine Rx

NEW YORK, Dec. 21, 2017 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on RPRX, ALDX, NEOT, and BLRX which can be accessed for free by signing up to www.wallstequities.com/registration. On Wednesday, the NASDAQ Composite ended the day at 6,960.96, down 0.04%; the Dow Jones Industrial Average edged 0.11% lower, to finish at 24,726.65; and the S&P 500 closed at 2,679.25, marginally slipping 0.08%. US markets saw five out of nine sectors finishing the day in red and four in green. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Repros Therapeutics Inc. (NASDAQ: RPRX), Aldeyra Therapeutics Inc. (NASDAQ: ALDX), Neothetics Inc. (NASDAQ: NEOT), and BioLine Rx Ltd (NASDAQ: BLRX). All you have to do is sign up today for this free limited time offer, click the link below: www.wallstequities.com/registration

Repros Therapeutics

The Woodlands, Texas-based Repros Therapeutics Inc.'s stock finished Wednesday's session 2.10% higher at $0.64 with a total trading volume of 721,864 shares. The stock has gained 48.40% in the past month and 111.15% over the past three months. The Company's shares are trading above their 50-day and 200-day moving averages by 29.07% and 9.16%, respectively. Moreover, shares of Repros Therapeutics, which focuses on the development of various drugs to treat hormonal and reproductive system disorders for male and female in the US, have a Relative Strength Index (RSI) of 66.44. Get the full research report on RPRX for free by clicking below at: www.wallstequities.com/registration/?symbol=RPRX

Aldeyra Therapeutics

Shares in Lexington, Massachusetts headquartered Aldeyra Therapeutics Inc. declined 1.55%, ending yesterday's session at $6.35 with a total trading volume of 52,460 shares. The stock has gained 36.56% over the past twelve months and 18.69% on an YTD basis. The Company's shares are trading above their 200-day moving average by 17.65%. Moreover, shares of Aldeyra Therapeutics, which focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the US and internationally, have an RSI of 45.63. Gain free access to the research report on ALDX at: www.wallstequities.com/registration/?symbol=ALDX

Neothetics

On Wednesday, San Diego, California headquartered Neothetics Inc.'s stock saw a rise of 1.04%, to close the day at $1.67. A total volume of 89,029 shares was traded. The Company's shares have advanced 23.70% in the last one month, 362.60% in the previous three months, 60.58% over the last twelve months, and 49.11% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 31.91% and 37.89%, respectively. Additionally, shares of Neothetics, which develops therapeutics for the aesthetic market, have an RSI of 73.83. Register for your free report coverage on NEOT at: www.wallstequities.com/registration/?symbol=NEOT

BioLine Rx

Shares in Jerusalem, Israel headquartered BioLine Rx Ltd ended the day 0.93% higher at $1.09. A total volume of 302,618 shares was traded. The stock has gained 12.37% over the last twelve months and 18.48% since the start of this year. The Company's shares are trading above their 50-day and 200-day moving averages by 0.87% and 8.55%, respectively. Furthermore, shares of BioLine Rx, which engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs, have an RSI of 51.97. Get the free research report on BLRX at: www.wallstequities.com/registration/?symbol=BLRX

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Wall St. Equities